6190.TSE · PhoenixBio Co., Ltd

-

Please sign in to comment on 6190.TSE

1 Comment

Admin

3 years, 7 months ago

PhoenixBio Co., Ltd is currently in a long term uptrend where the price is trading 2.7% above its 200 day moving average.

From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.

PhoenixBio Co., Ltd's total revenue sank by 35.9% to $200M since the same quarter in the previous year.

Its net income has dropped by 185.1% to $-80M since the same quarter in the previous year.

Based on the above factors, PhoenixBio Co., Ltd gets an overall score of 2/5.

ISIN	JP3803010002
Industry	Biotechnology
Sector	Healthcare
CurrencyCode	JPY
Exchange	TSE

PE Ratio	61.13
Market Cap	2B
Target Price	None
Beta	0.68
Dividend Yield	0.0%

ABOUT

PhoenixBio Co., Ltd

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments. Its contract study services in the field of drug discovery and development includes DMPK studies; safety studies; viral hepatitis-related studies; efficacy and safety studies for human specific nucleic acids, antibody, or polypeptide medicines; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The company was founded in 2002 and is headquartered in Higashihiroshima, Japan.

6190.TSE · PhoenixBio Co., Ltd

-

PhoenixBio Co., Ltd

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest PhoenixBio Co., Ltd using a moving average strategy